CT-guided interstitial high-dose-rate brachytherapy of lung malignancies: Efficacy and Safety

• Conditions: C34; C78.0; Malignant neoplasm of bronchus and lung; Secondary malignant neoplasm of lung

• Registration Number: DRKS00011204
• Lead Sponsor: niversitätsklinikum Magdeburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2017-01-10
• Study Completion: 2017-01-19
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 174

Inclusion Criteria

Patients with inoperable lung tumors where HDR-brachytherapy is an adequate treatment option and who have been treated in the period from March 2006 to January 2015.

Exclusion Criteria

Treatment of recurring tumor that has already been treated with brachytherapy

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
ocal response after CT-guided brachytherapy of lung malignancies. Following RECIST criteria, local response is defined by shrinking of target lesions. Evaluation is based on available follow-up CT scans.

Secondary Outcome Measures

Name	Time	Method
Progression-free survival (PFS), Overall Survival (OS), Safety